Morgan Stanley analyst Jeffrey Hung downgraded Intra-Cellular Therapies (NASDAQ: ITCI) from Overweight to Equalweight with a price target ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE